InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar)
货号 #SIM0041
克隆号:
Elotuzumab
反应种属:
Human
￥2,448 - ￥84,656
产品详情
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Elotuzumab, making it ideal for research use. Elotuzumab is a humanized monoclonal antibody that reacts with the cell surface glycoprotein CD319, which is commonly known as signaling lymphocytic activation molecule family member 7 (SLAMF7). SLAMF7 is highly expressed on myeloma cells, and in normal tissues, its expression is reported in natural killer (NK) cells, plasma cells, spleen cells, lymph nodes, peripheral blood leukocytes, bone marrow cells, etc. SLAMF7 is suggested to interact with SH2D1A, SH2D1B, PTPN6/SHP-1, PTPN11/SHP-2, INPP5D/SHIP1, CSK, and FYN proteins. Functionally, SLAMF7 is a self-ligand receptor of the SLAM family, and it is involved in the regulation and interconnection of both innate and adaptive immunity. Elotuzumab directly activates NK cells through both the SLAMF7 pathway and Fc receptor signaling. Elotuzumab also increases the expression of CD69 (on NK cells) and enhances IFN γ secretion and granzyme B biosynthesis, independent of Fc receptor signaling. In myeloma cells, based on in vitro studies, Elotuzumab is reported to target SLAMF7 and facilitate the interaction with NK cells for promoting myeloma cell death through the antibody-dependent cellular cytotoxicity (ADCC) mechanism. Elotuzumab disrupts the cell adhesion-mediated mechanisms of drug resistance in multiple myeloma cells by inhibiting their binding to bone marrow stromal cells in vitro. Elotuzumab is shown to reduce the growth of SLAMF7+ human multiple myeloma OPM2 xenografts in mice. Experiments involving in vitro as well as in vivo preclinical models demonstrated that a combination of Elotuzumab with the thalidomide derivative lenalidomide leads to enhanced activation of NK cells and increased anti-tumor activity.参数
| 同种型 | Human IgG1, κ |
|---|---|
| 推荐的同型对照 | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| 推荐稀释缓冲液 | InVivoPure pH 7.0 Dilution Buffer |
| 免疫原 | Human SLAMF7 |
| Reported Applications | in vivo functional assays in vitro functional assays ELISA Western blot Immunoprecipitation Flow cytometry |
| 形式 | PBS, pH 7.0 Contains no stabilizers or preservatives |
| 内毒素 | <0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay |
| 聚合 | <5% Determined by SEC |
| 纯化 | >95% Determined by SDS-PAGE |
| 无菌性 | 0.2 μM filtration |
| 生产 | Purified from cell culture supernatant in an animal-free facility |
| 分子量 | 150 kDa |
| 小鼠病原体试验 | Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Minute Virus: Negative Mouse Hepatitis Virus: Negative Reovirus Screen: Negative Lymphocytic Choriomeningitis virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Mouse Rotavirus: Negative Theiler's Murine Encephalomyelitis: Negative Ectromelia/Mousepox Virus: Negative Hantavirus: Negative Polyoma Virus: Negative Mouse Adenovirus: Negative Sendai Virus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Mouse Cytomegalovirus: Negative K Virus: Negative |
| 保存 | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
推荐产品
-
Recommended Isotype Control(s)
RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
